Inovio closed up 214% on November 2, 2026, its first session after Voceryq’s FDA approval, while rival Precigen fell 26% on the new RRP competition.
Last updated: November 3, 2026
Inovio stock settled at $1.89 on Monday, up 213.7% from Friday’s $0.60 close, in its first session after Voceryq’s accelerated approval. Precigen, maker of the only competing therapy, fell 25.9% to $5.14 on the same label.
This page covers the first trading verdict on Voceryq and its reported launch terms, the SIMPLAAFY readout and the rest of Monday’s TCT 2026 tape, Blackstone’s $455 million bet on Boston Scientific’s shock pump, and the week’s IPO ledger, with primary sources throughout.
How did the market react to Voceryq’s approval?
Inovio closed Monday at $1.89, up 213.7% from Friday’s $0.6024, in the first reaction session after the FDA’s Friday evening accelerated approval of Voceryq for adults with recurrent respiratory papillomatosis. Precigen, whose Papzimeos was the first approved RRP therapy in August 2025, closed at $5.14, down 25.9% from Friday’s $6.94. Both percentages are our arithmetic from exchange settled closes.
The two moves are the same event read from opposite sides. Friday’s approval converted Inovio from a cash constrained development story into a commercial company with a priced product, and it converted Precigen’s RRP franchise from a monopoly into half of a duopoly. The sector offered no cover: the XBI closed down 2.5% at 152.05 against a 0.5% dip in the S&P 500, so both prints carried signal rather than tape.
How much does Voceryq cost?
Voceryq carries a list price of $115,000 per dose, or $460,000 for the complete four dose series, according to MedCity News, which reported the figures from Inovio’s Monday morning conference call. Chief commercial officer Steve Egge said on the call that the price is consistent with Precigen’s RRP immunotherapy, per the same report. Inovio has not published the price in a release, and no other outlet we could confirm had independently carried the number by Monday evening, so treat the figure as attributed rather than company documented.
The parity is the story. Papzimeos launched at $115,000 per vial in 2025, so the second entrant in a market Precigen estimates at roughly 27,000 US adults has chosen to match rather than undercut. Pricing power in ultra rare markets usually survives a second entrant; Monday was the day that assumption was tested in RRP and held.
How do Voceryq and Papzimeos compare?
| Voceryq (Inovio) | Papzimeos (Precigen) | |
|---|---|---|
| Approval | Accelerated, October 30, 2026; confirmatory trial required | Traditional, August 2025; first RRP therapy |
| Platform | Plasmid DNA immunotherapy, delivered intramuscularly with the CELLECTRA electroporation device | Adenoviral vector immunotherapy, subcutaneous injections |
| Regimen | Four doses, one every three weeks, after surgical debulking | Injection series after debulking; label calls for additional surgery before doses three and four if papillomas are visible, per MedCity News |
| Pivotal result | 7 of 26 evaluable adults, 27%, needed no surgery over 12 months (RRP-001) | Traditional approval on complete response data in adults |
| List price | $115,000 per dose, $460,000 per series (per MedCity News, from the company call) | $115,000 per vial, the same series cost per MedCity News |
| Eligibility note | Label requires a set number of prior surgeries, per the company call coverage | No equivalent prior surgery count reported |
Both products target HPV types 6 and 11, the viruses behind the papillomas, and both still require surgery first. Neither label removes the scalpel; the race is over how long patients stay out of the operating room afterward.
When will Voceryq reach patients?
Inovio said it expects to begin shipping Voceryq within roughly 60 days, with full commercial launch in the first quarter of 2027 behind a contracted Syneos field force. The company told investors it is fully funded for the launch into the first quarter of 2027, and, per MedCity News, acknowledged it will need more capital and is evaluating options. That capital line is worth holding onto: Inovio ended June with $36.7 million and raised $20 million in July at far lower prices. Monday’s close triples the currency it can sell. No new offering had been announced as of Monday evening; our searches surfaced only stale offering releases from November 2025 and earlier in 2026, which we discarded on date checks.
What did the SIMPLAAFY trial show at TCT 2026?
SIMPLAAFY, a randomized trial of 1,857 patients at 86 US sites, found that two simpler drug regimens after left atrial appendage closure with Boston Scientific’s Watchman FLX Pro were each noninferior to the standard six months of dual antiplatelet therapy at six months, with less bleeding and equivalent 0.7% ischemic stroke rates. The results were a late breaker at TCT 2026 in San Diego on Monday and were published simultaneously in JAMA. The company release is the primary source.
| Arm | Regimen after implant | Six month result |
|---|---|---|
| Aspirin only | Aspirin alone throughout | Noninferior to dual antiplatelet therapy, less bleeding |
| Reduced dose NOAC | Reduced dose anticoagulant for three months, then aspirin | Noninferior, less bleeding; device related thrombus 0.9% vs 3.4% for the comparator (P=0.01) |
| Comparator | Aspirin plus clopidogrel for six months, then aspirin | Ischemic stroke 0.7%, matched by both test arms |
The release gives no bleeding percentages, noninferiority margins, or per arm counts; those live in the JAMA paper. The simplified regimens remain investigational after Watchman implantation, and the quoted study co chair is a paid Boston Scientific consultant, per the release footnote. The commercial logic is plain even so: the harder it is to keep a patient on dual antiplatelet therapy, the easier it is to justify the device when one aspirin will do. More than 800,000 patients have received Watchman devices to date, per the company.
What is Blackstone funding at Boston Scientific?
After Monday’s close, Blackstone Life Sciences announced a $455 million collaboration to jointly fund development of Boston Scientific’s VITALYST temporary percutaneous circulatory support system, a miniature heart pump for cardiogenic shock following acute myocardial infarction. The release calls it the first time the two firms will jointly fund a Boston Scientific product. It discloses no funding split, no milestones or repayment terms, no development stage, and no trial names; we are stating those absences rather than guessing. The strategic read sits in the device evidence wars: shock pumps are exactly the category where Johnson & Johnson’s Impella is fighting a randomized data deficit, and outside capital now underwrites the next entrant’s evidence bill.
What did Johnson & Johnson present on Impella on Monday?
The TCT 888 analysis, presented Monday afternoon, reported cardiovascular mortality of 3.4% at discharge among 522 Impella supported high risk PCI patients in a US registry, with Kaplan Meier rates of 4.7% at 30 days and 6.5% at 90 days, figures Johnson & Johnson describes as numerically lower than the roughly 8% reported in the randomized CHIP-BCIS3 study. The caveats from Sunday’s release carry forward: these are observational registry data compared across trials, with no confidence intervals disclosed, and the presenter is a paid J&J consultant per the release. A third analysis, a PROTECT III subgroup built to resemble the CHIP-BCIS3 population, presents Tuesday morning. The randomized answer, PROTECT IV, is anticipated in 2027.
How are the newest biotech IPOs trading?
Aspen Neuroscience completed its IPO on Monday, selling 9,375,000 shares at $15.00 for gross proceeds of about $140.6 million, per an Investing.com report of the company’s 8-K; that is the base deal, with the report silent on the overallotment option. The stock’s second session did not cooperate: ASPE fell 12.4% to $13.04, now 13.1% below its offer. Bambusa Therapeutics rose 6.7% to close at exactly its $16.00 offer price. Both percentages are our arithmetic. Two sessions in, the window’s newest class has one broken deal and one at face value, while the delivery end of the market keeps getting paid; Inovio’s Monday is the loudest data point yet.
Which stocks moved on Monday’s news?
Settled closes, with percentage moves computed by us against Friday’s closes.
| Ticker | Close | Move | Context |
|---|---|---|---|
| INO | $1.89 | +213.7% | First session after Voceryq approval |
| PGEN | $5.14 | −25.9% | RRP monopoly becomes a duopoly |
| HTFL | $54.49 | −7.7% | First reaction to the positive P4 noninferiority data; sellers met the print |
| SYK | $306.81 | +5.1% | Rebound after Friday’s 6.4% drop on the lowered outlook |
| CAPR | $7.24 | +13.5% | No disclosure we could find; deramiocel decision due November 22 |
| ASPE | $13.04 | −12.4% | Second session; 13.1% below the $15 offer |
Context: XBI 152.05, down 2.5%; SPY 752.10, down 0.5%. Capricor’s move came with no disclosure our searches could find Monday night; the items that surfaced were stale earlier vintages, and we assign no cause.
Frequently asked questions
What is Voceryq? Voceryq is Inovio’s plasmid DNA immunotherapy for adults with recurrent respiratory papillomatosis, approved by the FDA under accelerated approval on October 30, 2026. It is delivered into muscle with the company’s CELLECTRA electroporation device over four doses.
How much does Voceryq cost? MedCity News, reporting from Inovio’s November 2 conference call, puts the list price at $115,000 per dose and $460,000 for the full four dose series, matching Precigen’s Papzimeos. Inovio has not published the price in a release.
When will Voceryq be available? Inovio expects to begin shipping within roughly 60 days of approval, with a full commercial launch in the first quarter of 2027.
Is Voceryq the first treatment for recurrent respiratory papillomatosis? No. Precigen’s Papzimeos, approved in August 2025, was the first. Voceryq is the first DNA medicine approved by the FDA, a characterization the company makes and we attribute to it.
What is recurrent respiratory papillomatosis? A rare disease in which HPV types 6 and 11 cause wart like growths in the airway that must be repeatedly removed by surgery. The FDA cites about 1,000 new US adult cases a year; Precigen estimates roughly 27,000 US adults live with it.
Why did Inovio stock rise 214% on November 2? It was the first full trading session after Friday evening’s approval of Voceryq, the company’s first approved product.
Why did Precigen stock fall 26%? Voceryq’s approval ends Papzimeos’s run as the only approved RRP therapy, and Monday was the first session to price the competition.
What did SIMPLAAFY show? In 1,857 patients after Watchman FLX Pro implantation, aspirin alone and a reduced dose anticoagulant were each noninferior to six months of dual antiplatelet therapy at six months, with less bleeding, per Boston Scientific’s release and a simultaneous JAMA publication.
Does SIMPLAAFY change post implant care today? Not yet. The simplified regimens are described by the company as investigational after Watchman implantation; the data support, but do not by themselves rewrite, labeling and guidelines.
What is the VITALYST heart pump? A next generation miniature percutaneous heart pump from Boston Scientific for cardiogenic shock after heart attack. Blackstone Life Sciences committed $455 million on November 2 to jointly fund its development; deal terms were not disclosed.
How much did Aspen Neuroscience raise in its IPO? About $140.6 million gross, from 9,375,000 shares at $15.00, with the offering completed November 2, per an Investing.com report of the company’s 8-K.
When does Amgen report third quarter results? Amgen reports third quarter 2026 results on Tuesday, November 3, after the market close.
What is BridgeBio’s BBP-418? A candidate for limb girdle muscular dystrophy with an FDA action date of November 27, 2026, per BioSpace. If approved it would be the first therapy for the disease.
What happens at TCT on Tuesday? Johnson & Johnson’s PROTECT III subgroup analysis built to resemble the CHIP-BCIS3 population presents Tuesday morning, the final session of the meeting.
Sources
Primary sources: Boston Scientific SIMPLAAFY press release (November 2, 2026); Blackstone Life Sciences press release via Business Wire (November 2, 2026); Johnson & Johnson MedTech Impella TCT release (November 1, 2026); Inovio Voceryq approval release (October 30, 2026); Aspen Neuroscience Form 8-K as reported by Investing.com (November 2, 2026); exchange settled closing prices, November 2, 2026, with percentage moves computed by BioMed Nexus.
Trade coverage: MedCity News on Voceryq pricing and the Inovio call (November 2, 2026); pharmaphorum on the approval and launch timing (November 2, 2026); Investing.com on Monday’s premarket move (November 2, 2026); BioSpace on BridgeBio BBP-418 (November 2, 2026).
Related coverage
Read our full report on Inovio’s Voceryq approval and the 27% surgery free result behind it, our analysis of Iovance’s 35% drop on lung cancer data it called positive, our coverage of Abbott’s $8.5 billion nutrition spinoff, and our report on Treasury’s proposed outbound investment curbs on biotech.
